Nosis Bio Announces Development Candidate Nomination for Lead Fibrosis Program
Fibrosis affects over 100 million people globally and remains a high-burden, underserved condition that causes progressive scarring of critical organs such as the lungs, kidneys, and heart. Despite its prevalence, the field has seen limited progress, with existing treatments offering only modest efficacy and being constrained by systemic toxicity and poor tolerability.
Nosis Bio has designed a new option for patients: a cell-targeted therapeutic that selectively silences fibrotic drivers only in the pathogenic cells responsible for disease. This precision approach enables superior efficacy, a clean safety profile with minimal off-target effects, and a broad therapeutic index that unlocks the potential for long-term treatment and meaningful clinical impact in an area with significant patient need.
Key data supporting the DC nomination include:
Superior efficacy compared to standard-of-care therapeutics in head-to-head preclinical studies
A clean safety profile at 100-fold the anticipated therapeutic dose, with no dose-limiting toxicities observed
Demonstrated repeat dosing with no immunogenicity or anti-drug antibody (ADA) generation observed
'This milestone reflects our belief that the future of medicine lies in delivering potent therapeutics precisely to the cells that need them,' said Jim Martineau, CEO and Co-Founder of Nosis Bio. 'Unlike viral or lipid-based approaches, our cell-targeted platform avoids systemic toxicity and immunogenicity, simplifies manufacturing, and expands delivery to tissues and cell types that were previously out of reach. With our lead candidate nominated and a world-class team in place, we're focused on advancing rapidly to the clinic to bring safer, more effective treatments to patients.'
Nosis Bio's lead candidate was developed using the company's Connexa platform, an AI-native system designed to overcome key challenges with targeted delivery and drug design. In particular, Connexa has enabled cell-targeted delivery across seven tissues including the lung, kidney, heart, brain, muscle, small intestine, and key immune cell populations.
In addition to its program in fibrosis, Nosis is advancing a pipeline of cell-targeted therapeutics in immunology and inflammatory disease and is collaborating with leading pharmaceutical companies to apply its platform broadly across high-value indications.
About Nosis Bio
Nosis Bio is an AI-native biotechnology company pioneering cell-targeted gene silencing through its proprietary Connexa platform. By integrating physics-informed deep learning, drug design, and a seamlessly connected wet lab platform, Nosis designs medicines to silence disease-causing genes in precise cell types. The approach enables highly specific, safe, redosable, efficacious, and cost-effective therapeutics for diseases with high unmet need. Nosis is backed by leading institutional investors and has ongoing therapeutic collaborations with major pharmaceutical partners. For more information, visit www.nosisbio.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
MediaCo Reports Second Quarter Net Revenue of $31.2 Million and First Half of 2025 Net Revenue of $59.3 Million
NEW YORK--(BUSINESS WIRE)-- Financial Results Net Revenue. Year-to-date Net Revenue was $59.3 million, up $26.4 million, or 80%, from the prior year, driven primarily by new Audio and Video segment assets from the April 2024 Estrella Acquisition. Net Loss. Year-to-date Net Loss was $17.4 million, an improvement of $34.6 million from the prior year, primarily due to higher revenue and lower corporate costs related to the April 2024 Estrella Acquisition. These gains were partially offset by higher operating, depreciation, and amortization expenses tied to the Estrella Acquisition, along with a prior-year change in fair value of warrant shares liability. Net Loss margin improved to (29)% from (158)% in the prior-year period. Adjusted EBITDA. Year-to-date Adjusted EBITDA was $2.9 million, up $7.4 million from the prior year, driven by higher revenue and improved operational management. Adjusted EBITDA margin improved to 5% from a negative margin in the prior-year period. Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. Please refer to the 'Definitions and Disclosures Regarding Non- GAAP Financial Information' section herein, the reconciliations at the end of this press release and additional information on our website. 2025 Second Quarter Financial Summary 2025 First Half Financial Summary (1) Net Income margin is Net Income as a percentage of Net Revenue. Adjusted EBITDA margin is Adjusted EBITDA as a percentage of Net Revenue. (2) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. Please refer to the 'Definitions and Disclosures Regarding Non-GAAP Financial Information' section herein, the reconciliations at the end of this press release and additional information on our website. Expand Albert Rodriguez, MediaCo CEO and President, commented, 'We're proud to report a 19% year-over-year revenue increase this quarter, clear proof that our business is not only strong but gaining real momentum. Even more compelling is the 345% surge in first half digital revenue, which now accounts for 33.0% of our total ad income. This growth is fueled by our deep connection with multicultural audiences and the cultural relevance we deliver across every platform. It's a powerful validation of our strategy and indicates that MediaCo is leading the charge in today's digital-first economy. This quarter delivered record revenue, with P18–49 growth in five of the last seven months. EstrellaTV was the only Spanish-language broadcast network to post year-over-year prime-time growth for the full quarter—proof of our consistent performance and enduring audience connection.' Debra DeFelice, CFO and Treasurer, commented, 'MediaCo delivered a record second quarter, reflecting continued strength across our portfolio. Growth was driven by increases in radio and TV advertising revenue, record-breaking digital performance, and disciplined expense management. Our successful integration of Estrella Media assets from the most recent acquisition, combined with the progressive realization of synergies across markets and multiple delivery platforms, is fueling strong, sustainable results. We remain focused on delivering strong operating performance, enhancing cash flow, and executing on our long-term growth strategy, while advancing our content offerings and accelerating digital expansion. These initiatives position us to capitalize on emerging opportunities in the second half of the year.' Company and Business Highlights MediaCo Holding Inc. (Nasdaq: MDIA) is a diverse-owned, multi-platform media company serving multicultural audiences across the U.S. Through a network of iconic brands—including Hot 97, WBLS, EstrellaTV, Estrella News, Que Buena Los Angeles and the Don Cheto Radio Network—MediaCo reaches over 20 million people monthly via television, radio, digital, and streaming platforms. The company's innovative and culturally resonant content spans music, news, and entertainment across major local and national markets. New Programming: EstrellaTV is poised for continued growth with new sports, original, and acquired programming. The network secured multi-year rights to all Tigres, Tigres Femenil, Juarez, and Juarez Femenil Liga MX home games across all platforms. It also acquired multiplatform rights to the live music reality show Objetivo Fama and greenlit another season of Tengo Talento, Mucho Talento: Nueva Era for fall. Events: The 31st annual Summer Jam sold out the Prudential Center, featuring A Boogie, Wit Da Hoodie, Gunna, GloRilla and more and is back in June 2026, promising an even bigger show. In celebration of Cinco de Mayo, MediaCo's Spanish-language radio stations hosted sold out music festivals in Los Angeles, Houston and Dallas with over 40,000 in attendance. Digital & Streaming: MediaCo expects remarkable year-over-year digital and streaming revenue growth, fueled by EstrellaTV's Spanish-language brands and rising demand for CTV and FAST channels on major platforms. FAST watch time and monetized CTV ad inventory grew significantly in Q2. EstrellaTV and Estrella News were ranked as the top Latino-focused mixed IP FAST channels in the most recent Amagi/Ampere report. In Q2, FAST monthly watch time topped 310M minutes and monetized premium CTV ad inventory rose 290% YoY. MediaCo expanded its FAST footprint and ad mix with WAPA+ and Todos Novelas via Hemisphere Media. HOT 97's digital platforms amplified Summer Jam with record engagement in social reach up 1,000% to 38M users and web/app visitors up nearly 80% YoY. Hot 97 TV, a new FAST channel for Hip Hop and Afro culture, is set to launch this summer and is an example of the many initiatives with Trace to expand Afro-Urban content globally. HOT 97 and WBLS also launched commercial-free stations on TuneIn's premium service for new revenue opportunities. Radio: In early 2025, MediaCo's radio division grew primetime A25-54 audiences 24% vs. the prior four months, outpacing the market's 18% growth. Gains were led by KBUE/LA (+56%), KRQB/Riverside/San Bernardino (+46%), Dallas stations (+38% combined), Houston (+19%), and New York (+14% combined). Broadcast TV: EstrellaTV posted year-over-year prime time growth in five of the last seven months. Q2 P18-49 Mon–Sun prime averaged 15.3k viewers, up 23% YoY, driven by new originals and news programming. On May 14, the semifinal Liga MX match (Tigres UANL vs. Toluca) delivered the network's largest full coverage P18-49 audience ever (+157% vs. season average). June marked the third straight monthly gain, with Mon–Fri prime up 29% YoY. Local TV: EstrellaTV Local saw strong year-over-year growth in the combined April–May book averages. Three of the network's largest owned-and-operated stations posted gains in weekday prime among P18-49: KRCA/LA nearly doubled its audience (+96%), QFAA/Dallas grew +49%, and KZJL/Houston surged +143%. WGEN/Miami also delivered impressive results, up +198% in weekday prime among P25-54. Forward-Looking Statements This communication includes or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended ('Exchange Act'). You can identify these forward-looking statements by our use of words such as 'intend,' 'plan,' 'may,' 'will,' 'project,' 'estimate,' 'anticipate,' 'believe,' 'expect,' 'continue,' 'potential,' 'opportunity' and similar expressions, whether in the negative or affirmative. Such forward-looking statements, which speak only as of the date hereof, are based on managements' estimates, assumptions and beliefs regarding our future plans, intentions and expectations. We cannot guarantee that we will achieve these plans, intentions or expectations. All statements regarding our expected financial position, business, results of operations and financing plans are forward-looking statements. Actual results or events could differ materially from the plans, intentions or expectations disclosed in the forward-looking statements we make. We have included important facts in various cautionary statements in this communication that we believe could cause our actual results to differ materially from forward-looking statements that we make. The forward-looking statements do not reflect the potential impact of any future acquisitions, mergers or dispositions. We undertake no obligation to update or revise any forward-looking statements because of new information, future events or otherwise. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. For more details on factors that could affect these expectations, please see MediaCo's other filings with the Securities and Exchange Commission. Definitions and Disclosures Regarding Non-GAAP Financial Information We define Adjusted EBITDA as consolidated Operating loss adjusted to exclude restructuring expenses, business combination transaction costs, unusual and non-recurring expenditures and non-cash compensation included within operating expenses, as well as the following line items presented in our Statements of Operations: Depreciation and amortization, Loss on disposal of assets, change in fair value of warrant shares liability and Other income. Alternatively, Adjusted EBITDA is calculated as Net loss, adjusted to exclude Provision for income taxes, Interest expense, net, Depreciation and amortization, Loss on disposal of assets, Change in fair value of warrant shares liability, Other income, and Other adjustments. We use Adjusted EBITDA, among other measures, to evaluate the Company's operating performance. This measure is among the primary measures used by management for the planning and forecasting of future periods, as well as for measuring performance for compensation of executives and other members of management. We believe this measure is an important indicator of our operational strength and performance of our business because it provides a link between operational performance and operating income. It is also a primary measure used by management in evaluating companies as potential acquisition targets. We believe the presentation of this measure is relevant and useful for investors because it allows investors to view performance in a manner similar to the method used by management. We believe it helps improve investors' ability to understand our operating performance and makes it easier to compare our results with other companies that have different capital structures or tax rates. In addition, we believe this measure is also among the primary measures used externally by our investors, analysts and peers in our industry for purposes of valuation and comparing our operating performance to other companies in our industry. Since Adjusted EBITDA is not a measure calculated in accordance with GAAP, it should not be considered in isolation of, or as a substitute for, operating loss or net loss as an indicator of operating performance and may not be comparable to similarly titled measures employed by other companies. Adjusted EBITDA is not necessarily a measure of our ability to fund our cash needs. Because it excludes certain financial information compared with operating loss and compared with consolidated net loss, the most directly comparable GAAP financial measures, users of this financial information should consider the types of events and transactions which are excluded. For a reconciliation of these non-GAAP financial measurements to the GAAP financial results cited in this news announcement, please see the supplemental tables at the end of this release. About MediaCo Holding Inc. MediaCo Holding Inc. (Nasdaq: MDIA) is a diverse-owned, multi-platform media company serving multicultural audiences across the U.S. Through a network of iconic brands—including Hot 97, WBLS, EstrellaTV, Estrella News, Que Buena Los Angeles and the Don Cheto Radio Network—MediaCo reaches over 20 million people monthly via television, radio, digital, and streaming platforms. The company's innovative and culturally resonant content spans music, news, and entertainment across major local and national markets. More info at MEDIACO HOLDING INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Six Months Ended June 30, Change (Dollars in thousands) 2025 2024 $ % NET REVENUES $ 59,275 $ 32,908 26,367 80 OPERATING EXPENSES: Operating expenses 63,986 41,297 22,689 55 Corporate expenses 3,147 6,835 (3,688 ) (54 ) Depreciation and amortization 3,466 1,564 1,902 122 Loss on disposal of assets 144 5 139 2,780 Total operating expenses 70,743 49,701 21,042 42 OPERATING LOSS (11,468 ) (16,793 ) 5,325 (32 ) OTHER INCOME (EXPENSE): Interest expense, net (7,609 ) (3,918 ) (3,691 ) 94 Change in fair value of warrant shares liability — (31,027 ) 31,027 N/A Other income 2,230 20 2,210 11,050 Total other expense (5,379 ) (34,925 ) 29,546 (85 ) LOSS BEFORE INCOME TAXES (16,847 ) (51,718 ) 34,871 (67 ) PROVISION FOR INCOME TAXES 559 266 293 110 NET LOSS $ (17,406 ) $ (51,984 ) 34,578 (67 ) Expand MEDIACO HOLDING INC. NON-GAAP FINANCIAL MEASURES RECONCILIATIONS OF NET LOSS TO EBITDA AND ADJUSTED EBITDA (1) AND NET LOSS MARGIN TO ADJUSTED EBITDA MARGIN (1) Three Months Ended June 30, Six Months Ended June 30, (Dollars in thousands) 2025 2024 2025 2024 Net revenues $ 31,245 $ 26,202 $ 59,275 $ 32,908 Net Loss $ (8,521 ) $ (48,125 ) $ (17,406 ) $ (51,984 ) % Margin (28 )% (184 )% (29 )% (158 )% Provision for income taxes 279 182 559 266 Interest expense, net 3,855 3,782 7,609 3,918 Depreciation and amortization 1,697 1,431 3,466 1,564 EBITDA $ (2,690 ) $ (42,730 ) $ (5,772 ) $ (46,236 ) Loss on disposal of assets 5 5 144 5 Change in fair value of warrant shares liability — 31,027 — 31,027 Other income (2,119 ) (10 ) (2,230 ) (20 ) Other adjustments 6,595 6,486 10,776 10,725 Adjusted EBITDA (1) $ 1,791 $ (5,222 ) $ 2,918 $ (4,499 ) % Margin (1) 6 % (20 )% 5 % (14 )% (1) We define Adjusted EBITDA as consolidated Operating loss adjusted to exclude restructuring expenses, business combination transaction costs, unusual and non-recurring expenditures and non-cash compensation included within operating expenses, as well as the following line items presented in our Statements of Operations: Depreciation and amortization, Loss on disposal of assets, change in fair value of warrant shares liability and Other income. Alternatively, Adjusted EBITDA is calculated as Net loss, adjusted to exclude Provision for income taxes, Interest expense, net, Depreciation and amortization, Loss on disposal of assets, Change in fair value of warrant shares liability, Other income, and Other adjustments. We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of net revenue. We use Adjusted EBITDA and Adjusted EBITDA margin, among other measures, to evaluate the Company's operating performance. These measures are among the primary measures used by management for the planning and forecasting of future periods, as well as for measuring performance for compensation of executives and other members of management. We believe these measures are an important indicator of our operational strength and performance of our business because they provide a link between operational performance and operating income. They are also primary measures used by management in evaluating companies as potential acquisition targets. We believe the presentation of these measures is relevant and useful for investors because it allows investors to view performance in a manner similar to the method used by management. We believe they help improve investors' ability to understand our operating performance and make it easier to compare our results with other companies that have different capital structures or tax rates. In addition, we believe these measures are also among the primary measures used externally by our investors, analysts and peers in our industry for purposes of valuation and comparing our operating performance to other companies in our industry. Since Adjusted EBITDA and Adjusted EBITDA margin are not measures calculated in accordance with GAAP, they should not be considered in isolation of, or as a substitute for, operating loss or net loss, or net loss margin as indicators of operating performance and may not be comparable to similarly titled measures employed by other companies. Adjusted EBITDA and Adjusted EBITDA margin are not necessarily measures of our ability to fund our cash needs. Because they exclude certain financial information compared with operating loss, consolidated net loss, and consolidated net loss margin, the most directly comparable GAAP financial measures, users of this financial information should consider the types of events and transactions which are excluded. Expand
Business Wire
2 hours ago
- Business Wire
WOW Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of WideOpenWest, Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of WideOpenWest, Inc. (NYSE: WOW) to affiliates of DigitalBridge Investments, LLC and Crestview Partners for $5.20 per share is fair to WideOpenWest shareholders. Halper Sadeh encourages WideOpenWest shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether WideOpenWest and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for WideOpenWest shareholders; (2) determine whether DigitalBridge and Crestview are underpaying for WideOpenWest; and (3) disclose all material information necessary for WideOpenWest shareholders to adequately assess and value the merger consideration. On behalf of WideOpenWest shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
3 hours ago
- Business Wire
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.400% senior notes due 2025 in the aggregate principal amount of $600 million, and (iii) the remainder for general corporate purposes. The offering is expected to close on August 18, 2025, subject to customary closing conditions. Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may be accessed through the SEC's website at Alternatively, the issuer, the underwriters or any dealer participating in the offering will arrange to send the prospectus and prospectus supplement upon request by calling Barclays at 1-888-603-5847, BofA Securities at 1-800-294-1322, Citigroup at 1-800-831-9146, J.P. Morgan at 212-834-4533 and MUFG at 1-877-649-6848. These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. DISCLOSURE NOTICES Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned 'Forward-Looking Statements and Factors That May Affect Future Results' and 'Item 1A. Risk Factors,' in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at or on request from Zoetis.
